EPT Disclosure
March 31 2010 - 6:45AM
UK Regulatory
TIDMNPH
RNS Number : 4891J
Piper Jaffray Ltd
31 March 2010
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS
WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS
BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
(Rule 38.5(b) of the Takeover Code)
1. KEY INFORMATION
+------------------------------+----------------------------------------------+
| Name of exempt principal | Piper Jaffray Ltd. |
| trader | |
+------------------------------+----------------------------------------------+
| Company dealt in | Neuropharm Group plc |
+------------------------------+----------------------------------------------+
| Class of relevant security | Ord 10p |
| to which the dealings being | |
| disclosed relate (Note 1) | |
+------------------------------+----------------------------------------------+
| Date of dealing | 30 March 2010 |
+------------------------------+----------------------------------------------+
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
(a) Interests and short positions (following dealing) in the class of
relevant security dealt in (Note 2)
+------------------------------+---------------------------------------------------+-----------------------+
| | Long | Short |
| | | |
+------------------------------+---------------------------------------------------+-----------------------+
| | Number | Number |
| | (%) | (%) |
+------------------------------+---------------------------------------------------+-----------------------+
| (1) Relevant securities | 74,349 0.24% | |
| | | |
+------------------------------+---------------------------------------------------+-----------------------+
| (2) Derivatives (other than | | |
| options) | | |
| | | |
+------------------------------+---------------------------------------------------+-----------------------+
| (3) Options and agreements | | |
| to purchase/sell | | |
| | | |
+------------------------------+---------------------------------------------------+-----------------------+
| Total | 74,349 0.24% | |
| | | |
+------------------------------+---------------------------------------------------+-----------------------+
(b) Interests and short positions in relevant securities of the company,
other than the class dealt in (Note 2)
+------------------------------+----------------------+-----------------------+
| Class of relevant security: | Long | Short |
| | | |
+------------------------------+----------------------+-----------------------+
| | Number | Number |
| | (%) | (%) |
+------------------------------+----------------------+-----------------------+
| (1) Relevant securities | | |
| | | |
+------------------------------+----------------------+-----------------------+
| (2) Derivatives (other than | | |
| options) | | |
| | | |
+------------------------------+----------------------+-----------------------+
| (3) Options and agreements | | |
| to purchase/sell | | |
| | | |
+------------------------------+----------------------+-----------------------+
| Total | | |
| | | |
+------------------------------+----------------------+-----------------------+
(c) Rights to subscribe (Note 2)
+------------------------------+----------------------------------------------+
| Class of relevant security: | Details |
| | |
+------------------------------+----------------------------------------------+
| | |
+------------------------------+----------------------------------------------+
3. DEALINGS (Note 3)
(a) Purchases and sales
+-------------------------+------------------------+--------------------------+
| Purchase/sale | Number of securities | Price per unit (Note 4) |
| | | |
+-------------------------+------------------------+--------------------------+
| Buy | 13,000 | 10.00p |
+-------------------------+------------------------+--------------------------+
(b) Derivatives transactions (other than options)
+--------------+----------------+-----------------------+---------------------+
| Product | Long/short | Number of securities | Price per unit |
| name, | (Note 5) | (Note 6) | (Note 4) |
| e.g. CFD | | | |
+--------------+----------------+-----------------------+---------------------+
| | | | |
| | | | |
+--------------+----------------+-----------------------+---------------------+
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
+--------------+-------------+--------------+----------+-----------+--------+---------------+
| Product | Writing, | Number of | Exercise | Type, | Expiry | Option |
| name, | selling, | securities | price | e.g. | | money |
| e.g. call | purchasing, | to which the | | American, | date | paid/received |
| option | varying | option | | European | | per unit |
| | etc. | relates | | etc. | | (Note 4) |
| | | (Note 6) | | | | |
+--------------+-------------+--------------+----------+-----------+--------+---------------+
| | | | | | | |
+--------------+-------------+--------------+----------+-----------+--------+---------------+
(ii) Exercising
+-------------------------+------------------------+--------------------------+
| Product name, e.g. call | Number of securities | Exercise price per unit |
| option | | (Note 4) |
| | | |
+-------------------------+------------------------+--------------------------+
| | | |
| | | |
+-------------------------+------------------------+--------------------------+
(d) Other dealings (including new securities) (Note 3)
+-------------------------+------------------------+--------------------------+
| Nature of transaction | Details | Price per unit (if |
| (Note 7) | | applicable) (Note 4) |
| | | |
+-------------------------+------------------------+--------------------------+
| | | |
| | | |
+-------------------------+------------------------+--------------------------+
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
+------------------------------------------------------------------------------+
| Full details of any agreement, arrangement or understanding between the |
| person disclosing and any other person relating to the voting rights of any |
| relevant securities under any option referred to on this form or relating to |
| the voting rights or future acquisition or disposal of any relevant |
| securities to which any derivative referred to on this form is referenced. |
| If none, this should be stated. |
+------------------------------------------------------------------------------+
| |
| |
| |
+------------------------------------------------------------------------------+
Is a Supplemental Form 38.5(b) attached? (Note 8) NO
+--------------------------------------------+---------------------------------+
| Date of disclosure | 31 March 2010 |
+--------------------------------------------+---------------------------------+
| Contact name | Norman Gould |
+--------------------------------------------+---------------------------------+
| Telephone number | 020 3142 8780 |
+--------------------------------------------+---------------------------------+
| Name of offeree/offeror with which | Neuropharm Group plc |
| connected | |
+--------------------------------------------+---------------------------------+
| Nature of connection (Note 9) | Adviser and broker |
+--------------------------------------------+---------------------------------+
Notes
The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website at
www.thetakeoverpanel.org.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
EMMUARBRRSAOORR
Neuropharm (LSE:NPH)
Historical Stock Chart
From Nov 2024 to Dec 2024
Neuropharm (LSE:NPH)
Historical Stock Chart
From Dec 2023 to Dec 2024
